SLNO
Price
$64.96
Change
+$2.24 (+3.57%)
Updated
Sep 26 closing price
Capitalization
3.45B
39 days until earnings call
VRDN
Price
$20.19
Change
+$1.11 (+5.82%)
Updated
Sep 26 closing price
Capitalization
1.65B
52 days until earnings call
Interact to see
Advertisement

SLNO vs VRDN

Header iconSLNO vs VRDN Comparison
Open Charts SLNO vs VRDNBanner chart's image
Soleno Therapeutics
Price$64.96
Change+$2.24 (+3.57%)
Volume$1.56M
Capitalization3.45B
Viridian Therapeutics
Price$20.19
Change+$1.11 (+5.82%)
Volume$625.09K
Capitalization1.65B
SLNO vs VRDN Comparison Chart in %
Loading...
SLNO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VRDN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
SLNO vs. VRDN commentary
Sep 27, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is SLNO is a StrongBuy and VRDN is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 27, 2025
Stock price -- (SLNO: $65.02 vs. VRDN: $20.18)
Brand notoriety: SLNO and VRDN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: SLNO: 40% vs. VRDN: 29%
Market capitalization -- SLNO: $3.33B vs. VRDN: $1.56B
SLNO [@Biotechnology] is valued at $3.33B. VRDN’s [@Biotechnology] market capitalization is $1.56B. The market cap for tickers in the [@Biotechnology] industry ranges from $97.91B to $0. The average market capitalization across the [@Biotechnology] industry is $1.89B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

SLNO’s FA Score shows that 0 FA rating(s) are green whileVRDN’s FA Score has 0 green FA rating(s).

  • SLNO’s FA Score: 0 green, 5 red.
  • VRDN’s FA Score: 0 green, 5 red.
According to our system of comparison, VRDN is a better buy in the long-term than SLNO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

SLNO’s TA Score shows that 5 TA indicator(s) are bullish while VRDN’s TA Score has 4 bullish TA indicator(s).

  • SLNO’s TA Score: 5 bullish, 3 bearish.
  • VRDN’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, SLNO is a better buy in the short-term than VRDN.

Price Growth

SLNO (@Biotechnology) experienced а +18.78% price change this week, while VRDN (@Biotechnology) price change was +3.86% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.14%. For the same industry, the average monthly price growth was +9.25%, and the average quarterly price growth was +54.64%.

Reported Earning Dates

SLNO is expected to report earnings on Nov 05, 2025.

VRDN is expected to report earnings on Nov 18, 2025.

Industries' Descriptions

@Biotechnology (+4.14% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SLNO($3.45B) has a higher market cap than VRDN($1.65B). SLNO YTD gains are higher at: 44.516 vs. VRDN (5.321). SLNO has higher annual earnings (EBITDA): -176.1M vs. VRDN (-340.62M). VRDN has more cash in the bank: 563M vs. SLNO (287M). VRDN has less debt than SLNO: VRDN (21.3M) vs SLNO (52.8M). SLNO has higher revenues than VRDN: SLNO (32.7M) vs VRDN (305K).
SLNOVRDNSLNO / VRDN
Capitalization3.45B1.65B209%
EBITDA-176.1M-340.62M52%
Gain YTD44.5165.321837%
P/E RatioN/AN/A-
Revenue32.7M305K10,721%
Total Cash287M563M51%
Total Debt52.8M21.3M248%
FUNDAMENTALS RATINGS
SLNO vs VRDN: Fundamental Ratings
SLNO
VRDN
OUTLOOK RATING
1..100
672
VALUATION
overvalued / fair valued / undervalued
1..100
68
Overvalued
94
Overvalued
PROFIT vs RISK RATING
1..100
5785
SMR RATING
1..100
9899
PRICE GROWTH RATING
1..100
6244
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
3450

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SLNO's Valuation (68) in the Medical Specialties industry is in the same range as VRDN (94) in the Biotechnology industry. This means that SLNO’s stock grew similarly to VRDN’s over the last 12 months.

SLNO's Profit vs Risk Rating (57) in the Medical Specialties industry is in the same range as VRDN (85) in the Biotechnology industry. This means that SLNO’s stock grew similarly to VRDN’s over the last 12 months.

SLNO's SMR Rating (98) in the Medical Specialties industry is in the same range as VRDN (99) in the Biotechnology industry. This means that SLNO’s stock grew similarly to VRDN’s over the last 12 months.

VRDN's Price Growth Rating (44) in the Biotechnology industry is in the same range as SLNO (62) in the Medical Specialties industry. This means that VRDN’s stock grew similarly to SLNO’s over the last 12 months.

VRDN's P/E Growth Rating (100) in the Biotechnology industry is in the same range as SLNO (100) in the Medical Specialties industry. This means that VRDN’s stock grew similarly to SLNO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
SLNOVRDN
RSI
ODDS (%)
Bullish Trend 2 days ago
84%
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
87%
Bullish Trend 2 days ago
74%
Momentum
ODDS (%)
Bullish Trend 2 days ago
82%
Bearish Trend 2 days ago
85%
MACD
ODDS (%)
Bullish Trend 2 days ago
76%
Bearish Trend 2 days ago
81%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
83%
Bearish Trend 2 days ago
87%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
85%
Bullish Trend 2 days ago
83%
Advances
ODDS (%)
Bullish Trend 3 days ago
85%
Bullish Trend 4 days ago
81%
Declines
ODDS (%)
Bearish Trend 11 days ago
85%
Bearish Trend 2 days ago
85%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
82%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
86%
View a ticker or compare two or three
Interact to see
Advertisement
SLNO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VRDN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
ABSZX20.830.22
+1.07%
AB Discovery Value Z
ERHSX13.690.09
+0.66%
Eaton Vance Worldwide Health Sci R
GCPCX21.030.09
+0.43%
Gateway Equity Call Premium C
CAPOX10.480.02
+0.19%
Absolute Capital Opportunities Instl
FZAFX26.73N/A
N/A
Fidelity Advisor Equity Growth Z

SLNO and

Correlation & Price change

A.I.dvisor indicates that over the last year, SLNO has been loosely correlated with NKTX. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if SLNO jumps, then NKTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SLNO
1D Price
Change %
SLNO100%
+3.57%
NKTX - SLNO
40%
Loosely correlated
+2.00%
SYRE - SLNO
40%
Loosely correlated
+4.04%
GRCE - SLNO
38%
Loosely correlated
+0.32%
NUVL - SLNO
38%
Loosely correlated
+4.99%
VRDN - SLNO
37%
Loosely correlated
+5.82%
More

VRDN and

Correlation & Price change

A.I.dvisor indicates that over the last year, VRDN has been loosely correlated with SYRE. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if VRDN jumps, then SYRE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VRDN
1D Price
Change %
VRDN100%
+5.82%
SYRE - VRDN
58%
Loosely correlated
+4.04%
CRNX - VRDN
56%
Loosely correlated
+27.92%
NUVL - VRDN
55%
Loosely correlated
+4.99%
OCUL - VRDN
52%
Loosely correlated
+2.37%
BEAM - VRDN
52%
Loosely correlated
-0.52%
More